Press Release
Veristat and Karyopharm Therapeutics Inc. Agreement
HOLLISTON, Mass. – June 15, 2014 – Veristat, a full service Contract Research Organization, announced today that Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases, has entered into a Preferred Provider agreement with Veristat. Under this agreement, Veristat provides strategic statistical consulting and biometrics services, including study design, statistical analysis and data presentation.
